Professor, Medicine, University of North Carolina at Chapel Hill School of Medicine
Gastroenterology
Dr. Paul A. Watkins, MD
|
|
Give Review
Paul Watkins practices Gastroenterology. He went to medical school at Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18/49 in Research/PrimaryCare. He received 3 awards: "Fellow (AGAF)", "Elected Member" and "Whos Who in Medicine and Healthcare". Paul Watkins is a published physician. He published 68 publications, including: 'Beyond miR-122: Identification of MicroRNA Alterations in Blood During a Time Course of Hepatobiliary Injury and Biliary Hyperplasia in Rats.' He accepts all Medicare patients.
Publications
- Beyond miR-122: Identification of MicroRNA Alterations in Blood During a Time Course of Hepatobiliary Injury and Biliary Hyperplasia in Rats.
- Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
- MITOsym®: A Mechanistic, Mathematical Model of Hepatocellular Respiration and Bioenergetics.
- Sensitivity to hepatotoxicity due to epigallocatechin gallate is affected by genetic background in diversity outbred mice.
- The clinical liver safety assessment best practices workshop: rationale, goals, accomplishments and the future.
- Liver safety assessment: required data elements and best practices for data collection and standardization in clinical trials.
- Causality Assessment for Suspected DILI During Clinical Phases of Drug Development.
- Systems pharmacology modeling predicts delayed presentation and species differences in bile Acid-mediated troglitazone hepatotoxicity.
- Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.
- A Systems Biology Approach Utilizing a Mouse Diversity Panel Identifies Genetic Differences Influencing Isoniazid-Induced Microvesicular Steatosis.
- Liver biomarker and in vitro assessment confirm the hepatic origin of aminotransferase elevations lacking histopathological correlate in beagle dogs treated with GABAA...
- Use of a systems model of drug-induced liver injury (DILIsym(®)) to elucidate the mechanistic differences between acetaminophen and its less-toxic isomer, AMAP, in mice.
- Managing the risk of drug-induced liver injury.
- Linking physiology to toxicity using DILIsym®, a mechanistic mathematical model of drug-induced liver injury.
- A Mouse Diversity Panel Approach Reveals the Potential for Clinical Kidney Injury Due to DB289 Not Predicted by Classical Rodent Models.
- Combination Lopinavir and Ritonavir Alter Exogenous and Endogenous Bile Acid Disposition in Sandwich-Cultured Rat Hepatocytes.
- An analysis of N-acetylcysteine treatment for acetaminophen overdose using a systems model of drug-induced liver injury.
- Effect of Oxygen Concentration on Viability and Metabolism in a Fluidized-bed Bioartificial Liver Using 31P and 13C NMR Spectroscopy.
- Pilot study of rosiglitazone as an in vivo probe of paclitaxel exposure.
- Genetic basis of susceptibility to drug-induced liver injury: what have we learned and where do we go from here?
- Metabolomics in toxicology: preclinical and clinical applications.
- Polymerase γ gene POLG determines the risk of sodium valproate-induced liver toxicity.
- Quantitative analyses and transcriptomic profiling of circulating messenger RNAs as biomarkers of rat liver injury.
- Acetaminophen dosing of humans results in blood transcriptome and metabolome changes consistent with impaired oxidative phosphorylation.
- Effects of a prolonged standardized diet on normalizing the human metabolome.
- Biomarkers for the diagnosis and management of drug-induced liver injury.
- Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans.
- Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.
- Using controlled clinical trials to learn more about acute drug-induced liver injury.
- Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.
- Drug-induced liver injury network.
- Further characterization of a furanocoumarin-free grapefruit juice on drug disposition: studies with cyclosporine.
- The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: an in vitro-in vivo evaluation.
- Tolcapone: an efficacy and safety review (2007).
- Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP/SLC10A1)by bosentan: a mechanism for species differences in hepato...
- Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial.
- Steroid and xenobiotic receptor and vitamin D receptor crosstalk mediates CYP24 expression and drug-induced osteomalacia.
- Increased CYP3A4 copy number in TONG/HCC cells but not in DNA from other humans.
- A furanocoumarin-free grapefruit juice establishes furanocoumarins as the mediators of the grapefruit juice-felodipine interaction.
- MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype.
- Drug-induced liver injury: summary of a single topic clinical research conference.
- Intestinal and hepatic CYP3A4 catalyze hydroxylation of 1alpha,25-dihydroxyvitamin D(3): implications for drug-induced osteomalacia.
- Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5.
- CYP3A probes can quantitatively predict the in vivo kinetics of other CYP3A substrates and can accurately assess CYP3A induction and inhibition.
- Two major grapefruit juice components differ in time to onset of intestinal CYP3A4 inhibition.
- Do men and women differ in proximal small intestinal CYP3A or P-glycoprotein expression?
- Role of cytochrome P450 phenotyping in cancer treatment.
- Insight into hepatotoxicity: The troglitazone experience.
- Idiosyncratic liver injury: challenges and approaches.
- Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties.
- New insights into drug absorption: studies with sirolimus.
- 6'7'-Dihydroxybergamottin contributes to the grapefruit juice effect.
- Are patients with elevated liver tests at increased risk of drug-induced liver injury?
- Contributions of CYP3A4, P-glycoprotein, and serum protein binding to the intestinal first-pass extraction of saquinavir.
- Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.
- CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults.
- Pharmacogenetics and clinical gastroenterology.
- Did this drug cause my patient's hepatitis?
- Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.
- Growth hormone secretion pattern is an independent regulator of growth hormone actions in humans.
- Cytochrome P450 3A4 and P-glycoprotein mediate the interaction between an oral erythromycin breath test and rifampin.
- Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans.
- Identification of a novel route of extraction of sirolimus in human small intestine: roles of metabolism and secretion.
- Exploring BSEP inhibition-mediated toxicity with a mechanistic model of drug-induced liver injury.
- Mechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILI.
- A mechanistic model of drug-induced liver injury AIDS the interpretation of elevated liver transaminase levels in a phase I clinical trial.
- Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance.
Schools
North Mississippi Medical Center
Mississippi State University
Doctors Specialties
- Family Medicine
- Gastroenterology
Accepted Insurances
- Blue Cross Blue Shield of Alabama
- Medicare MCR
Awards
- Fellow (AGAF)
- Elected Member
- Whos Who in Medicine and Healthcare
Education
-
New York Presbyterian Hospital - Cornell Campus -
Weill Cornell Medical College of Cornell University
Drug Facts
| NPI NUMBER | 1518279520 | |
| NPPES Provider LastName | WATKINS | |
| NPPES Provider FirstName | PAUL | |
| NPPES Provider ZIPCode | 365321766 | |
| NPPES Provider State | AL | |
| Specialty Description | Family Practice | |
| Total Claim Count | 1544.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 15.0 | |
| Percent Opioid Claims | 0.97 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1518279520 |
| Last Name Of The Provider | WATKINS |
| First Name Of The Provider | PAUL |
| View All |
Similar Doctors
|
|
Dr. Craig M. Dowden, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lynn E. Yonge, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Randall L. Hall, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Vickie G. Boggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Karl S. Self, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Christopher W. Ives, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen E. Winston, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert E. McAlister Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert H. Meichner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Stephen L. Coleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Susan A. Jordan, MD |